Frontiers in Medical Science Research, 2022, 4(5); doi: 10.25236/FMSR.2022.040501.
Wenzong Lu, Hang Ma
Department of Biomedical Engineering, College of Electronic and Information Engineering, Xi’an Technological University, Xi’an, Shaanxi Province, 710021, China.
Lung cancer is one of the cancers that seriously threaten human life, especially lung adenocarcinoma. Although various diagnostic and therapeutic methods continue to appear, the clinical outcomes are still gloomy. The gene coding and non-coding ribonucleic acid data of lung adenocarcinoma was analyzed by using the non-negative matrix factorization clustering, differential expression and survival analysis. Functional and pathway enrichment analysis was performed for each subtype. The computed tomography imaging features of lung adenocarcinoma were extracted and associated with weighted gene co-expression network analysis. All patients with lung adenocarcinoma could be significantly classified into three subtypes according to gene expression feature. The differential expressed genes were significantly enriched in biological processes including lung development, morphogenesis of an epithelium, receptor-mediated endocytosis for subtype 1, subtype 2, subtype 3, respectively. The number of special molecules is 340, 71, 109 for subtype 1, subtype 2, subtype 3, respectively. Some of them such as neuroendocrine convertase 1 for subtype 3, has_mir_10b for subtype 2, parathyroid hormone-related protein for subtype 1 and so on, were strongly associated with the integrate density feature in region of interest of computed tomography imaging. Subtypes of patients with lung adenocarcinoma could be accurately stratified by investigating the multi-omics data features, and several computed tomography imaging features are closely associated with the special molecules of each subtype, which is useful for selecting diagnosis and therapeutic methods.
Multi-omics; Lung cancer; Molecular subtype; Weighted gene co-expression network analysis
Wenzong Lu, Hang Ma. Lung Adenocarcinoma Subtyping and Feature Identification Based on Multi-omics Data Analysis. Frontiers in Medical Science Research (2022) Vol. 4, Issue 5: 1-9. https://doi.org/10.25236/FMSR.2022.040501.
[1] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., et al. (2021). Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer Journal for Clinicians. 71(3), 209-249.
[2] Liu, G. B., Pei, F., Yang, F. Q., Li, L. X., Amin, A. D., et al. (2017). Role of autophagy and apoptosis in non-small-cell lung cancer. International Journal of Molecular Sciences. 18(2), 367.
[3] Saito, M., Suzuki, H., Kono, K., Takenoshita, S., Kohno, T. (2018). Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surgery Today. 48(1), 1-8.
[4] Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., et al. (2017). Pd-1 and pd-l1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Frontiers in Pharmacology. 8, 561.
[5] Gelatti, A. C. Z., Drilon, A., Santini, F. C. (2019). Optimizing the sequencing of tyrosine kinase inhibitors (tkis) in epidermal growth factor receptor (egfr) mutation-positive non-small cell lung cancer (nsclc). Lung Cancer. 137, 113-122.
[6] Zhou, Q., Sun, C. C., Li, D. J. (2017). Towards mirna based therapeutics for lung cancer. Current Pharmaceutical Design. 23(39), 5971-5972.
[7] Ma, L. N., Cao, J. B., Liu, L., Du, Q., Li, Z., et al. (2019). Lncbook: A curated knowledgebase of human long non-coding rnas (vol 47, pg d128, 2019). Nucleic Acids Research. 47(5), 2699-2699.
[8] Wang, J. L., Cai, H. B., Dai, Z. X., Wang, G. (2019). Down-regulation of lncrna xist inhibits cell proliferation via regulating mir-744/ring1 axis in non-small cell lung cancer. Clinical Science. 133(14), 1567-1579.
[9] Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., et al. (2017). Lung cancer: Current therapies and new targeted treatments. Lancet. 389(10066), 299-311.
[10] Robles, A. I., Harris, C. C. (2017). Integration of multiple "omic" biomarkers: A precision medicine strategy for lung cancer. Lung Cancer. 107, 50-58.
[11] Concolino, P., Capoluongo, E. (2019). Detection of brca1/2 large genomic rearrangements in breast and ovarian cancer patients: An overview of the current methods. Expert Review of Molecular Diagnostics. 19(9), 795-802.
[12] Devarakonda, S., Morgensztern, D., Govindan, R. (2015). Genomic alterations in lung adenocarcinoma. Lancet Oncology. 16(7), E342-E351.
[13] Vigneswaran, J., Tan, Y. H. C., Murgu, S. D., Won, B. M., Patton, K. A., et al. (2016). Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 7(14), 18876-18886.
[14] Zhou, M., Leung, A., Echegaray, S., Gentles, A., Shrager, J. B., et al. (2018). Non-small cell lung cancer radiogenomics map identifies relationships between molecular and imaging phenotypes with prognostic implications. Radiology. 286(1), 307-315.
[15] Gevaert, O., Xu, J. J., Hoang, C. D., Leung, A. N., Xu, Y., et al. (2012). Non-small cell lung cancer: Identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-methods and preliminary results. Radiology. 264(2), 387-396.
[16] Badic, B., Hatt, M., Durand, S., Le Jossic-Corcos, C., Simon, B., et al. (2019). Radiogenomics-based cancer prognosis in colorectal cancer. Scientific Reports. 9, 9743.